DMAA — Drugs Made In America Acquisition Balance Sheet
0.000.00%
Last trade - 00:00- $256.97m
- $256.96m
Annual balance sheet for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | ARS | 10-K | 10-K |
| Standards: | — | USG | USG |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Short Term Investments | — | 0.001 | 0.006 |
| Prepaid Expenses | |||
| Total Current Assets | — | 0.005 | 0.012 |
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | — | 0.551 | 240 |
| Payable / Accrued | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | — | 0.796 | 0.376 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | — | 0.796 | 7.28 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | — | -0.245 | 233 |
| Total Liabilities & Shareholders' Equity | — | 0.551 | 240 |
| Total Common Shares Outstanding |